„Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway", NJPS, roč. 40, č. 2, s. 251–262, pro. 2025, doi: 10.54548/.